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Objective: Loss of function FTO mutations signiﬁcantly impact body composition in humans and mice, with Fto-deﬁcient mice reported to resist
the development of obesity in response to a high-fat diet (HFD). We aimed to further explore the interactions between FTO and HFD and determine
if FTO can inﬂuence the adverse metabolic consequence of HFD.
Methods: We studied mice deﬁcient in FTO in two well validated models of leptin resistance (HFD feeding and central palmitate injection) to
determine how Fto genotype may inﬂuence the action of leptin. Using transcriptomic analysis of hypothalamic tissue to identify relevant pathways
affected by the loss of Fto, we combined data from co-immunoprecipitation, yeast 2-hybrid and luciferase reporter assays to identify mechanisms
through which FTO can inﬂuence the development of leptin resistant states.
Results: Mice deﬁcient in Fto signiﬁcantly increased their fat mass in response to HFD. Ftoþ/ and Fto/ mice remained sensitive to the
anorexigenic effects of leptin, both after exposure to a HFD or after acute central application of palmitate. Genes encoding components of the
NFlB signalling pathway were down-regulated in the hypothalami of Fto-deﬁcient mice following a HFD. When this pathway was reactivated in
Fto-deﬁcient mice with a single low central dose of TNFa, the mice became less sensitive to the effect of leptin. We identiﬁed a transcriptional
coactivator of NFlB, TRIP4, as a binding partner of FTO and a molecule that is required for TRIP4 dependent transactivation of NFlB.
Conclusions: Our study demonstrates that, independent of body weight, Fto inﬂuences the metabolic outcomes of a HFD through alteration of
hypothalamic NFlB signalling. This supports the notion that pharmacological modulation of FTO activity might have the potential for therapeutic
beneﬁt in improving leptin sensitivity, in a manner that is inﬂuenced by the nutritional environment.
 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Genome-wide association studies (GWAS) have indicated that single
nucleotide polymorphisms (SNPs) on chromosome 16 within the ﬁrst
intron of FTO (FaT mass and Obesity related) are robustly associated
with human obesity [1]. These SNPs are also associated with obesity-
related anthropometric traits such as fat mass, leptin levels and waist-
to-hip ratio, as well as an increase in food intake and a reduction in
satiety. More detailed analyses have determined that the increase in
consumed energy in risk allele carriers appears due, at least in part, to
an increased in preference for energy-dense food, especially those
with a higher fat content [2,3]. FTO is a member of the ALKB family of
nucleic acid demethylases and has a high afﬁnity for 3-methylthymine
(3-meT) in DNA [4] as well as 3-methyluracil (3-meU; [4,5]) and 6-
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adiposity through effects on the expression of other neighbouring
genes including IRX3 [7] and RPGRIP1L [8]. Whatever the explanation
for the effects of intronic polymorphism on human adiposity, studies of
humans and mice carrying genetic variants that functionally perturb
FTO indicate that FTO itself is an important regulator of body size and
composition, with loss of function mutations being associated with low
body weight in humans [9] and mice [10,11,12] and transgenic
overexpression resulting in obesity in mice [13]. Fto is highly expressed
within the hypothalamus [1,4] and Fto mRNA levels in the arcuate
nucleus are reduced by fasting [4,14,15] and increased by high-fat
feeding [15,16]. Notably, Ftoþ/ and Fto/ mice have been re-
ported to be protected from the development of obesity on a high-fat
diet (HFD) [10] while high-fat feeding exacerbates the obesity of
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Original articleThe concept of “leptin resistance” has emerged to explain why obese
animals, with high circulating leptin levels, do not appear to demon-
strate the anorectic effects of leptin that are present in lean animals.
High-fat feeding is a classical model whereby resistance to leptin can
be induced in an experimental model. This can be replicated acutely by
the central infusion of fatty acids, including palmitate [17]. More
recently the notion has emerged that high-fat feeding and high central
exposure to lipids can induce a state of inﬂammation in the hypo-
thalamus and that this might be an important part of the induction of
leptin resistance [18].
In this study, we provide further evidence that Ftoþ/ and Fto/ mice
remain sensitive to the anorectic effects of leptin despite exposure to
either a HFD or the acute central administration of palmitate. We also
identify a transcriptional co-activator that physically and functionally
interacts with FTO to activate hypothalamic NFlB signalling pathways
that have previously been implicated in the pathogenesis of leptin
resistance.
2. MATERIAL AND METHODS
2.1. Mice
Fto deﬁcient mice were a generous gift from Prof. Roger Cox (MRC
Harwell, Oxford) and were generated and genotyped as previously
described [12]. All mice were maintained under controlled temperature
(22 C) and on a 12hr light, 12hr dark schedule (light on 07:00e
19:00). Food and water were available ad libitum unless otherwise
stated. All mice were weaned at 3 weeks of age onto a standard chow
(SDS RM3, Essex, UK). All protocols were in accordance with the
United Kingdom Home Ofﬁce legislation (Animal (Scientiﬁc Procedure)
Act 1986).
2.1.1. Dietary intervention
Standard chow throughout all studies was SDS RM3 (Essex, UK). High
fat diet used contains 60% of calories from fat, 20% from protein and
20% from Carbohydrate (D12492, Research Diet).
2.1.2. Body composition analysis
Body composition was determined using dual-energy X-ray absorpti-
ometry (DEXA, PIX-Imus2 Series Densimeters) under terminal anaes-
thetic (Dolethal, Vetoquinol UK Ltd).
2.1.3. Glucose homeostasis
Oral glucose tolerance test (OGTT; 2 g glucose/kg) was performed in
mice that were fasted for 6 h (beginning at 8AM) following 5 weeks on
a HFD. Brieﬂy, a bolus of 20% glucose was delivered into the stomach
by a gavage needle and blood for measurement of glucose was taken
by tail vein sampling at 0, 10, 20, 30, 60, 90 and 120 min and assayed
with a glucometer (AlphaTRAK2, Abbott Animal Health).
2.2. Intracerebroventricular experiments
To allow ICV injection, male mice aged between 10 and 13 weeks
underwent stereotaxic surgery to place an indwelling guide cannula
into the lateral ventricle. Mice were anaesthetised with a mix of inhaled
isoﬂuorane and oxygen and a 26 gauge steel guide cannula (internal
diameter 0.24 mm, outer diameter 0.46 mm, length 2 mm; Semat
International, UK) was implanted into the right lateral ventricle using
the following coordinates: 1.0 mm lateral from bregma, 0.5 mm
posterior to bregma; 2.0 mm depth. The guide cannula was secured to
the skull using quick-drying cyanoacrylate glue and dental cement
(Associated Dental Products, Wiltshire, UK), and a dummy cannula was
inserted. All animals received analgesia (Rimadyl, 5 mg/kg, Pﬁzer288 MOLECULAR METABOLISM 4 (2015) 287e298  2015 The Authors. Published by EAnimal Health, Kent, UK) and antibiotic (Teramycin LA, 60 mg/kg,
Pﬁzer Animal Health, Kent, UK) before being returned to their home
cage. Following surgery, mice were single housed throughout the
study, food intake and body weight was measured daily. Injections
were performed while mice were in their home cages and food
returned 60 min after the last injection.
2.2.1. Leptin responsiveness
8 week old male mice of each genotype were given either standard
chow diet or HFD for four weeks, and had indwelling guide cannula
placed as described above. Seven days post-surgery mice were
reassessed and only those that had remained weight stable or put on
weight were studied. After an overnight fast, mice received either 2 ml
of PBS or recombinant murine leptin (500 ng in 2 ml; Amgen) via the
cannula. Standard chow or high-fat diet was returned to the hopper
and the amount consumed after 4- and 24-hr was measured.
2.2.2. Palmitate injection
10e13 week old male mice maintained on standard chow were used.
Mice were fasted overnight and 1 ml of each injectant or corresponding
vehicle control was injected according to the respective experimental
set-up (Figures 3 & 5). A crossover design was used such that each
mouse served as its own control. Animals were allowed a washout
period of at least 5 days between treatments and the order of treat-
ments were re-randomized between experiments. Stock solution of
3.3 mM palmitate (Cat. 76119, Sigma) was prepared with 100% EtOH
at 60 C and further diluted with fatty acid-free BSA (Cat. A6003,
Sigma) to give a ﬁnal concentration of 66uM/ml. BSA or PBS Saline
vehicle injectants were prepared equivalently, but without palmitate or
recombinant mouse TNFa (aa 80e235; R & D System), respectively.
2.3. Immunohistochemistry
Adult male mice were deeply anesthetised with sodium pentobarbital
and were transcardially perfused with PBS followed by ice-cold 10%
formalin. After perfusion, brains were removed and post-ﬁxed in 15%
sucrose formalin then transferred to 30% (wt/vol) sucrose in PBS
overnight. Perfused brains were sectioned at 30 mm thickness on a
microtome in a one-in-four coronal series through the hypothalamus.
Phosphorylated STAT3 immunohistochemistry was performed as pre-
viously described [19] using a rabbit anti-pSTAT3 antibody (Cat.
No.9131; Cell Signaling Technology). Brieﬂy, tissues were treated
sequentially with 1% NaOH and 1% H2O2 for 20 min, 0.3% glycine for
10 min and 0.03% SDS for 10 min. Sections were then blocked with
normal goat serum and incubated with anti-pSTAT3 antibody (1:2000)
overnight at 4 C. The next day, sections were incubated with bio-
tinylated goat anti-rabbit antibody (1:2000, Dako) followed by avidin-
biotin complex solution (Elite ABC Kit, Vector Laboratories) and brown
precipitate development by diaminobenzidine solution (ImmPACTTM-
DAB, Vector Laboratories). pSTAT3-positive cells were clearly deﬁned by
visual inspection in the arcuate nucleus of hypothalami from mice given
central fatty acid pre-treatment followed by leptin. pSTAT3 positive cells
were counted bilaterally under a light microscope from matched sec-
tions ranging from bregma 1.22 to 2.30 mm (Paxinos Mouse Brain
Atlas). The investigator was blinded to the treatment group and
expressed counts as the total number of pSTAT3 positive cells per
section. Images were acquired with an Olympus BX41 microscope
equipped with the Colorview soft imaging system.
2.4. Quantitative real-time PCR
One hour after leptin injection, mice were euthanized by terminal
anaesthesia (Dolethal, Vetoquinol UK Ltd) and hypothalami rapidlylsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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removed and ﬂash frozen in liquid nitrogen and stored at 80 C until
further analysed.
Total RNA from the tissue of interest was puriﬁed with TRIsure (Bioline)
using a FastPrep 24 homogeniser (MP Biomedicals) according to the
manufacturer’s instructions. The RNA was reverse transcribed and
ampliﬁed using TaqMan Universal PCR Master Mix with TaqMan Assay
on demand kit (Applied Biosystems). Quantitative PCR reactions were
performed in duplicate and relative expression was determined for
target mRNA and adjusted for total mRNA content by hypoxanthine-
phosphoribosyl transferase (Hprt), TATA e binding protein (Tbp) and
b2 e macroglobulin (B2M). Quantitative PCR statistical analysis was
performed using Microsoft Excel. P-value was calculated using a two-
tailed distribution unpaired Student’s t-test and data expressed as
mean  SEM.
For the NFkB signalling pathway proﬁler PCR array (Mouse NFkB
Signalling Pathway, Qiagen), total RNA was reverse transcribed ac-
cording to the manufacturer’s instructions using 400 ng starting ma-
terial. Arithmetic mean of B2M, Heat shock protein 90 KDa alpha class
B member 1 (Hsp90ab1) and B-glucuronidase (Gusb) expression level
was used as loading controls.
2.5. Flag-tag pull down and endogenous immunoprecipitations
Mouse embryonic ﬁbroblasts (MEF) were obtained from Fto WT and
null mice. MEFs and HEK 293 cells were maintained in Dulbecco’s
Modiﬁed Minimal Essential Medium (DMEM5796, Sigma) supple-
mented with 10% foetal bovine serum at 37 C in the presence of 5%
CO2. For over expression studies, transient transfections were per-
formed using a CalPhos kit (for HEKs 293) from ClonTech and Neon
System (for MEFs) from Invitrogen according to the manufacturer’s
protocol. Flag-tag, FTO and TRIP4 IPs were performed as described
previously [20]. After the IPs, immunocomplexes were eluted using
glycine buffer (pH 3.0) at 4 C for 30 min. After the elution remaining
beads and eluate were resuspended in 1x sample buffer for Western
blot analysis.
2.6. Luciferase assays
For the luciferase study, assays were performed with the Cignal
NFkB Reporter Assay (Promega). Brieﬂy, MEF cells derived from Fto
null mice were transfected with the Cignal reporters which is a
mixture of an inducible NFkB- responsive ﬁreﬂy luciferase construct
and a constitutively expressing renilla luciferase construct, together
with various combinations of expression vectors under investigation.
“Empty” vector controls expresses GFP and was also used to
monitor consistency in transfection efﬁciency. All transfections were
performed with the Neon transfection system (Invitrogen), following
the manufacturer’s instructions, and enzymatic activities were
measured using a luminometer (DLReady; Berthold Technologies)
performed with the Dual-luciferase reporter system (Promega).
Brieﬂy, ﬁreﬂy luciferase reagent (LARII) was added to the test
sample followed by addition of equal amounts of renilla luciferase
reagent and ﬁreﬂy quenching reagent (Stop & Glo). The data are
represented as the ratio of ﬁreﬂy to renilla luciferase activity and is
the mean of at least three separate experiments performed in
triplicate.
2.7. Testing of the direct in vivo interaction between FTO and
TRIP4 in the Y2H system
Yeast two-hybrid is a widely used method for studying proteineprotein
interactions in vivo, so we used the commercially available Match-
maker Gold Yeast Two-Hybrid System (Clontech). In these assays, FTO
is expressed as a fusion to the GAL4 DNA-binding domain (BD), whileMOLECULAR METABOLISM 4 (2015) 287e298  2015 The Authors. Published by Elsevier GmbH. This is an o
www.molecularmetabolism.comTRIP4 is expressed as fusion to the GAL4 activation domain (AD). When
FTO and TRIP4 fusion proteins interact, the DNA-BD and AD are
brought into close proximity, thus activating transcription of four in-
dependent reporter genes (AUR1-C, ADE2, HIS3 and MEL1). The
combination of antibiotic, nutritional and colorimetric reporters means
false positive are reduced to a minimal and allow for “grading” of the
binding strength to be determined, with activation of all four reporters
suggesting the highest binding strength. Nine truncated fragments of
the human FTO functional domains were tested for their ability to bind
to the full length TRIP4 directly.
All of the procedures were performed according to the manufacturer’s
protocol (Clontech). Brieﬂy, full length or truncated constructs of FTO
were cloned into the vector pGBKT7 and were used to transfect the
yeast strain AH107 and the pGADT7-TRIP4 recombinant plasmids were
transfected into the yeast strand Y180. The yeast strains Y187-
pGADT7-TRIP4 and AH109-pGBKT7-FTO were tested for autono-
mous activation, and none of the constructs showed any self-
activation. The transfected strains were used for the yeast two-
hybrid mating assays testing the binding domains for interaction be-
tween FTO and TRIP4. The “mated” transformants were cultured in
medium for 20hr and then plated onto the appropriate selective me-
dium. The strength of the interaction was conﬁrmed by colonies
growing on the selective medium, with the highest binding denoted as
“þþþþ” assigned to colonies growing on fully selective medium;
while ““ was assigned to background colony growth. All data pre-
sented are repeats of at least 3 separate experiments and most of the
interactions were done with TRIP4 cloned into the vector pGADT7
(containing AD) and FTO cloned into vector pGBKT7 (containing BD);
but for a selection of interaction studies, the reverse were also assayed
to eliminate potential bias and the obtained results were comparable in
either cloning direction.
2.8. Statistical analysis
All data are presented as mean  SEM and have been analysed using
Microsoft Excel and GraphPad Prism 5. Single comparisons were made
using one- or two-tail Student’s t-test as speciﬁed in the respective
ﬁgure legends. Multiple comparisons were tested with ANOVA and
adjusted with Bonferroni’s post-test. Difference among groups were
considered signiﬁcant for p-values of <0.05.
3. RESULTS
3.1. Inﬂuence of Fto status on the change of body composition in
response to a HFD
We were intrigued by the previous reports that Fto-deﬁcient and haplo-
insufﬁcient mice did not develop obesity in response to a high-fat diet
[10] and initially set out to see if this phenomenon was readily repli-
cable. Eight week old WT, Ftoþ/ and Fto/ mice were given a 60%
HFD for ﬁve weeks and their body composition subsequently compared
to age-matched mice of the same genotypes that had been continu-
ously provided with regular chow for the same time period. As pre-
viously reported, on regular chow Fto/ mice had a signiﬁcant
reduction in total body weight (Figure 1A), fat mass (Figure 1B) and
lean mass (Figure 1C), as well as bone mineral density (Figure 1D),
when compared to WT littermates.
As expected, after ﬁve weeks on HFD diet, WT mice weighed 44%
more than mice fed chow (40.1  1.5 g vs 27.9  0.6 g; p < 0.001)
(Figure 1A). However, in contrast to previous reports both Ftoþ/ and
Fto/ signiﬁcantly increased their body mass on HFD. The response
of Ftoþ/ mice was not signiﬁcantly different from that of WT
(42.6  1.3 g on HFD vs 27.7  0.7 g on chow, a 53% increase;pen access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 289
Figure 1: Effect of exposure to a high-fat diet in Fto-deﬁcient mice. Effect of Fto-deﬁciency on anthropometric measurements of 13 week old male mice either on standard
chow or 5 weeks of 60% HFD. (A) Body weight; (B) total fat mass; (C) total lean mass and (D) Bone mineral density as measured by dual-energy X-ray absorptiometry (DEXA). (E)
Weights of dissected epididymal white adipose tissue and (F) subcutaneous white adipose tissue. Black bars denote Ftoþ/þ (n ¼ 17 chow, n ¼ 13 HFD); grey bars denote Ftoþ/
(n ¼ 20 chow, n ¼ 13 HFD); white bars denote Fto/ (n ¼ 13 chow, n ¼ 10 HFD). *p < 0.05; **p < 0.01; ***p < 0.001 following two-tailed t-test.
Original articlep < 0.001), while Fto/ mice increased their weight by 29%
(29.7  1.2 g on HFD vs 23  0.5 g on chow; p < 0.001).
We went on to analyse body composition in each genotype and
determined that the increase in body mass in each genotype was
primarily driven by a signiﬁcant increase in fat mass (Figure 1B &
Supplemental Figure 1A), indicating that Fto loss does not protect from
HFD diet induced obesity. Despite a lowered total absolute fat mass in
the Fto/ mice compared to WT and Ftoþ/ mice, there was no
difference in serum leptin levels between the three genotypes either on
regular chow (WT vs Ftoþ/ vs Fto/; 2.37  0.34 ng/ml vs
3.24  0.51 ng/ml vs 2.33  0.59 ng/ml, respectively, n.s.) or after a
HFD (WT vs Ftoþ/ vs Fto/; 25.11 2.7 ng/ml vs 27.5 5.8 ng/ml
vs 31.6  8.6 ng/ml, respectively, n.s.). Intriguingly, Fto genotype
appeared to have some inﬂuence on the distribution of body fat in
response to a HFD. WT mice given a HFD gained more visceral
epididymal fat (4.7  0.38 g) than subcutaneous fat (1.9  0.15 g;
p < 0.001) (Figure 1E, F & Supplemental Figure 1C, 1D). In contrast,
HFD fed Ftoþ/ mice with similar absolute fat mass as WT (Figure 1B),
had more subcutaneous than epididymal fat (3.2  0.17 g vs.
2.2  0.17 g, respectively; p < 0.001; Figure 1E,F), and displayed an
improved glucose tolerance as compared to WT mice on HFD
(Supplemental Figure 2).290 MOLECULAR METABOLISM 4 (2015) 287e298  2015 The Authors. Published by E3.2. Despite a signiﬁcant increase in fat mass, Fto-deﬁcient mice
remain leptin sensitive on a HFD
In light of these ﬁndings, we went on to test the sensitivity of all three
groups to central leptin administration. On a chow diet, all three ge-
notypes were responsive to the anorexigenic effects of leptin with Fto/
 mice demonstrating the most robust response (50% drop in 4hr food
intake; p< 0.001) (Figure 2A & Supplemental Figure 3A). As expected,
after ﬁve weeks on a HFD, WT mice had developed leptin resistance as
judged by a failure to reduce food intake in response to the same dose
of leptin that brought about a decrease in food intake in chow fed
animals. Intriguingly, obese HFD fed Fto-deﬁcient mice remained
sensitive to leptin in a gene-dosage manner, with Ftoþ/ mice
reducing their food intake by 20% (p< 0.01) and Fto/ mice by 50%
(p < 0.001) (Figure 2B & Supplemental Figure 3B).
3.3. Fto-deﬁcient mice remain sensitive to leptin after acute central
exposure to palmitate
Given that Fto is highly expressed within the hypothalamus, we
hypothesised that effects seen in Fto deﬁcient mice were a direct result
of loss of central expression of Fto. To investigate this further, we
utilised a second, well characterised model of acute leptin resistance,
that of central injection of palmitate [17] (Figure 3A). As expected, pre-lsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 2: Measurement of leptin sensitivity in Fto-deﬁcient mice exposed to a
high-fat diet. The ability of WT and Fto-deﬁcient male mice on chow and a HFD to
reduce food intake in response to an intracerebroventricular (icv) injection of leptin. A
single injection of 500 ng of leptin was administered centrally and food intake was
measured 4 h after food was returned to the hopper. (A) Leptin administration
decreased food intake signiﬁcantly in all mice on standard chow (Ftoþ/þ n ¼ 8, Ftoþ/
n ¼ 11, Fto/ n ¼ 6). (B) Leptin-induced anorexia is absent in WT mice with 5 weeks
of high-fat feeding but retained in Fto-deﬁcient mice (Ftoþ/þ n ¼ 10, Ftoþ/ n ¼ 15,
Fto/ n ¼ 7). Data are plotted as percentage of values obtained, with food intake in
the saline-treated control group in each genotype set as 100%. *p < 0.05; **p < 0.01;
***p < 0.001; NS ¼ not signiﬁcant following one-tailed t-test.treatment with palmitate prior to leptin injection induced almost
complete central leptin resistance in WT mice. However, Ftoþ/ and
Fto/ mice remained fully sensitive to leptin even after palmitate pre-
treatment, with both groups reducing food intake by approximately
40% (p < 0.001) in response to leptin (Figure 3A). This recapitulates
the phenotype seen after a 5 week exposure to HFD and argues that
the mechanisms underlying the maintained sensitivity to leptin in Ftoþ/
 and Fto/ mice are directly centrally mediated. In keeping with this
retained sensitivity to leptin after palmitate treatment, there was a
signiﬁcant increase in leptin-induced phosphorylation of STAT3 in the
hypothalamic ARC of Fto/ compared to WT mice (p < 0.05)
(Figure 3B,C). We did see an intermediate phenotype in the Ftoþ/
mice, although this was not statistically signiﬁcant (Figure 3C).
3.4. NFkB signalling pathway is down-regulated in Fto-deﬁcient
mice on HFD
We looked next to determine the underlying molecular mechanism that
allow Fto-deﬁcient mice to remain leptin sensitive on a HFD by
examining gene expression within the hypothalamus, a region critically
involved in appetite regulation and one in which Fto is highly expressed
(Supplemental Figure 9). Analysis of canonical leptin responsive genes
within the ARC showed no differences in expression of Agrp, Npy,MOLECULAR METABOLISM 4 (2015) 287e298  2015 The Authors. Published by Elsevier GmbH. This is an o
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HFD between WT and Fto/ mice (Supplemental Figure 4A).
We turned next to the pathways downstream of the leptin receptor.
Leptin signalling via STAT3 induces the expression of SOCS3 mRNA in
the hypothalamus, which inhibits the phosphorylation and activation of
JAK2. Over-activation of SOCS3 is a proposed mechanism for leptin
resistance; particularly in diet induced obese states. We found a sig-
niﬁcant reduction in Socs3 expression in the hypothalami of Fto
deﬁcient mice on a HFD as compared to WT mice (Figure 4A &
Supplemental Figure 4B). In addition to playing a role in leptin sig-
nalling, SOCS3 is also downstream of NFlB signalling, a pathway
known to be up-regulated within the medial-basal hypothalamus in
response to a HFD. We measured expression of Myd88, a key adapter
required for NFlB activation, and found that it too exhibited a signif-
icant reduced response in Fto deﬁcient mice on a HFD as compared to
WT mice (Figure 4A & Supplemental Figure 4B).
These ﬁndings prompted us to examine the NFlB pathway more
broadly and using a mouse NFlB signalling pathway proﬁler PCR
array, we measured the gene expression proﬁle of 84 components of
NFlB signalling within the hypothalami of WT, Ftoþ/ and Fto/mice
on chow and HFD. The array included genes that encode members of
the NFlB, IkB families, NFlB-responsive genes, extracellular ligands
and receptors that activate the pathway, as well as downstream ki-
nases and transcription factors. We found no difference in expression
pattern of NFlB pathway genes in the three different genotypes on a
chow diet (Supplemental Figure 5A), while, as expected, there was up-
regulation of 60 NFlB pathway genes in the hypothalami of WT mice
exposed to a HFD (Supplemental Figure 5B & Supplemental Table 1).
However, in Fto-deﬁcient mice on HFD, we found a co-ordinate down-
regulation of the NFlB pathway in a gene dosage dependent fashion,
with Fto/ mice displaying a greater effect than that seen in Ftoþ/
mice (Figure 4B, C & Supplemental Table 2). This co-ordinated down-
regulation of NFlB pathway gene expression was speciﬁc to the hy-
pothalamus and was not seen in other regions of the brain such as the
cortex and cerebellum, or in peripheral tissues such as epididymal fat
and skeletal muscle (Supplemental Figure 6).
In addition to the NFlB pathway, we also examined expression of a
number of key markers of endoplasmic reticulum stress (ER stress),
another cellular process that can cause inﬂammation during HFD
feeding and has been suggested to lie downstream of Myd88 signalling
[21]. However, no differences in expression were detected in several of
the markers of ER stress activation [22] between Fto/ and WT mice
(Supplemental Figure 4C).
3.5. TNFa activation of the NFlB pathway in Fto-deﬁcient mice
restores palmitate induced leptin resistance
To establish if down-regulation of the hypothalamic NFlB pathway
was causally related to the demonstrated leptin sensitivity, we used
centrally administered TNFa to reactivate the pathway in Fto-deﬁcient
mice prior to fatty acid administration (Figure 5).
Central TNFa treatment has previously been shown to activate the
NFlB pathway in the hypothalamus [23]. A dose of TNFa (10 pg) was
used that had no effect on 24hr food intake (saline vs TNFa, Ftoþ/
7.7  0.4 g vs 6.2  0.7 g, N.S; Fto/ 7.1  0.4 g vs 7.9  0.3 g,
n.s.) but up-regulated Nfkb2, Myd88, Tlr4 and Socs3 expression in the
hypothalami of Ftoþ/and Fto/ mice (Supplemental Figure 7). In
contrast to the PBS control treatment (Figure 5A,B), TNFa pre-
treatment resulted in sensitization of the Fto/ mice to palmitate,
leading to a blunted response to leptin (Figure 5B), similar to that seen
in the WT mice, where palmitate prior to leptin injection induced central
leptin resistance (Figure 3A). In Ftoþ/ mice, where NFlB pathwaypen access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 291
Figure 3: Measurement of leptin-sensitivity in Fto-deﬁcient mice injected centrally with palmitate. (A) Palmitate was administered 30 min prior to leptin to test for its ability
to block leptin-induced anorexia. Mice on standard chow from each genotype were fasted overnight prior to injection of palmitate or BSA control and followed by leptin, as
illustrated in the schematic of our experimental strategy (Ftoþ/þ n ¼ 10, Ftoþ/ n ¼ 9, Fto/ n ¼ 8). Data are plotted as a percentage of the value obtained with saline treatment.
(B) Effect of palmitate pre-treatment on leptin induced p-STAT3 immunostaining in representative coronal sections from Ftoþ/þ and Ftoþ/ mice. (C) Number of p-STAT3
immunoreactive arcuate nucleus neurons with n ¼ 3 mice per group. 3V ¼ third ventricle; ME ¼ median eminence. Bar ¼ 100um. Data are presented as mean  SEM. *,
p < 0.05; **, p < 0.01; ***, p < 0.001; NS ¼ not signiﬁcant following two-tailed t-test.
Original articlegene expression was modestly down-regulated (as compared to Fto/
) (Figure 4B; 4C; Supplemental Table 2), treatment with TNFa alone
was sufﬁcient to induce leptin resistance without palmitate treatment
(Figure 5A). Thus our data suggest that Fto inﬂuences the ability of a
HFD to induce central leptin resistance through alteration of hypo-
thalamic NFlB signalling.
3.6. FTO binds to TRIP4 and is necessary for TRIP4 dependent
transactivation of NFlB
We looked next for interacting partners to determine a possible
mechanistic link between FTO and NFlB signalling. Based on bio-
informatic analysis of FTO’s phylogenetic evolution, we focused on a
family of proteins that contained ASCH domains. Although FTO ho-
mologues exist in vertebrates and in marine algae, FTO of several
algae has an additional C-terminal ASCH domain (Supplemental292 MOLECULAR METABOLISM 4 (2015) 287e298  2015 The Authors. Published by EFigure 8A). It is a common observation that domains that are com-
ponents of one polypeptide in some species and separated in different
chains in other species enter the same functional pathway, and
frequently physically interact [24]. There are only three ASCH domain-
containing proteins in the mammalian genome, one of which is Thyroid
receptor interacting protein 4 (TRIP4), a known transcriptional coac-
tivator of NFlB [25]. Trip4 is highly expressed in the CNS, particularly
the hypothalamus (Supplemental Figure 9).
We ﬁrst showed in HEK cells transiently transfected with FLAG tagged
FTO, that FLAG antibodies were able to co-immunoprecipitate TRIP4
(Figure 6A). Next, by using mouse embryonic ﬁbroblasts (MEFs) ob-
tained from WT mice, we demonstrated that immunoprecipitation of
endogenous Fto could pull down endogenous Trip4 (Figure 6B
left panel) and vice versa (Figure 6B right panel). MEFs obtained from
Fto/ mice were included as negative controls.lsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
www.molecularmetabolism.com
Figure 4: Hypothalamic gene expression in Fto-deﬁcient mice exposed to a HFD. (A) Relative mRNA levels for leptin receptor (Ob-R), Myd88 and suppressor of cytokine
signalling (SOCS3) were determined by quantitative RT-PCR in the hypothalamus of mice from each genotype fed normal chow versus mice exposed to 5 weeks of high-fat diet.
Data are means  SEM. * ¼ p < 0.05 following two-tailed t-test. n ¼ 9e15 mice per group. Each mRNA was normalised to Hprt mRNA in the same sample. (B) Scatter plot of the
expression proﬁle of 84 genes encoding components of the NFkB pathway. Each dot represents a gene and is obtained by plotting the log of the average normalised signal intensity
of genes in the HFD state against the chow fed state. Green dots represent genes that are down-regulated with HFD and the red dots are those that are up-regulated during a HFD.
(C) Bar plot of genes encoding components of the NFkB pathway that are 1.5 fold down-regulated in Fto/ mice.To conﬁrm a direct interaction between FTO and TRIP4, we undertook an
orthogonal approach using the widely usedmethod for studying proteine
protein interactions in vivo, the Yeast-2-hybrid (Y2H) system. By deter-
mining the interaction of full length human TRIP4 with different deletion
mutants of FTO, we showed that amino acid residues 30e48 and 249e
269 in FTO are the epitopes that directly interact with TRIP4 (Figure 6C). In
the 3-dimensional structure, FTO binds to TRIP4 through two surface
mobile epitopes exposed at one side of FTO (Supplemental Figure 8B).MOLECULAR METABOLISM 4 (2015) 287e298  2015 The Authors. Published by Elsevier GmbH. This is an o
www.molecularmetabolism.comTo determine if FTO and TRIP4 functionally interact to inﬂuence the
NFlB pathway, we used MEFs obtained from Fto/ mice and tran-
siently transfected these with an NFlB-responsive luciferase reporter.
To this we additionally transfected a TRIP4 expression construct
together with a variety of constructs expressing tagged full-length FTO
or deletion mutants. The MEFs expressing either FTO or TRIP4 indi-
vidually, or expressing TRIP4 and N- or C-terminal FTO deletion mu-
tants, did not show an increase in luciferase signal. However, whenpen access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 293
Figure 5: Effects of central TNFa injection on palmitate induced leptin resistance. To test the ability of TNFa upregulation of NFkB pathway gene expression to induce leptin
resistance in palmitate treated Fto-deﬁcient mice, TNFa or PBS control was injected centrally, four hours prior to palmitate and then leptin administration. Overnight fasted (A) Ftoþ/
 mice (n ¼ 7 with PBS; n ¼ 10 with TNFa) or (B) Fto/ mice (n ¼ 7 with PBS; n ¼ 8 with TNFa) on standard chow were treated as illustrated in the schematic of our
experimental strategy. Data are presented as mean  SEM and are plotted as a percentage of the value obtained with saline treatment. *p < 0.05; **p < 0.01; ***p < 0.001;
NS ¼ not signiﬁcant following two-tailed t-test.
Original articleTRIP4 was expressed with either FLAG-tagged or Myc-tagged full
length FTO, there was up to a ﬁve-fold increase in luciferase signal
(Figure 6D). Thus, in the context of this cellular system, FTO appears to
be necessary for TRIP4-dependent transactivation of NFlB.
4. DISCUSSION
We report that mice deﬁcient in Fto signiﬁcantly increase their fat mass
in response to HFD and that Ftoþ/ and Fto/ mice remain sensitive to
the anorexigenic effects of leptin, both after exposure to a HFD or after
acute central application of palmitate. We show that genes encoding
components of the NFlB signalling pathway are down-regulated in Fto-
deﬁcient mice following a HFD. Further, when this pathway is reac-
tivated in Fto-deﬁcient mice with a single low central dose of TNFa, the
mice became less sensitive to the effects of leptin. We identify a
transcriptional coactivator of NFlB, TRIP4, as a binding partner of FTO
and a plausible candidate involved in mediating this phenomenon.
Our results are in contrast to the initial report by Fischer and colleagues
[10], where losing just one functional copy of Fto was reported to294 MOLECULAR METABOLISM 4 (2015) 287e298  2015 The Authors. Published by Eprotect animals from weight gain on a HFD. This difference could be
due to the diet used in our study, which contained 60% of its calories
from saturated fat, mostly derived from lard, whereas a diet with 42%
of calories from milk-fat was used in the previous report. Further
differences in the phenotype may be due to different gene targeting
strategies, with Fischer et al. deleting exons two and three of Fto,
whereas the model we report here only has exon 3 deleted.
We also report that despite a lowered fat mass in the Fto null mice,
there was no difference in serum leptin levels between the three ge-
notypes, either on regular chow or after a HFD. The determinants of
circulating leptin levels are complex, not fully understood and not
wholly determined by leptin sensitivity in the hypothalamus. At any
given level of fat mass circulating leptin levels vary widely [26]. This is
true even in conditions such as leptin receptor deﬁciency, where the
cause of the leptin resistance is known [27]. Interestingly, transgenic
mice carrying additional copies of Fto, in whom fat mass is increased,
actually show relative hypoleptinemia [13] suggesting that Fto gene
dosage may have an effect on leptin levels independent of its effect on
fat mass.lsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 6: FTO interacts with TRIP4, a transcriptional coactivator of NFkB. (A) HEK293 cells were transiently transfected with vector alone or Flag- FTO. Cells were harvested
after 48 h and resulting cell extracts were subjected to Flag immunoprecipitation using antibody against Flag protein. Flag immunoprecipitates were then eluted from the beads and
analysed further by western blotting. (B) MEFs derived from wild type and Fto null mice were grown for 24hr and harvested, after which endogenous FTO (left panel) or TRIP4 (right
panel) proteins were immunoprecipitated using antibodies against FTO and TRIP4. Resulting immunoprecipitates were analysed by western blotting using indicated antibodies. (C)
Schematic overview of the testing of the FTO binding epitopes that interact with TRIP4. Y2H experiments were performed to determine a direct interaction between full length TRIP4
and functional domain deletions of FTO. The results of this deletion mapping narrowed down the critical interacting domain of FTO to the region encoded by amino acids 30e48
and 249e269. The black lines mark the regions cloned into the yeast two-hybrid constructs and numbers in parentheses indicate amino acid number of each deletion mutants.
The ﬁve-point “grading” scale was used to determine the strength of the binding: “þþþþ” highest binding, “þþþ” high binding, “þþ” moderate binding, “þ” low binding and
“e“background binding. (D) Regulation of NFkB reporter activation by FTO-TRIP4 interactions were investigated using Fto null MEF cells transfected with a ﬁreﬂy luciferase NFkB
reporter vector, along with the indicated expression constructs and a control plasmid expressing renilla luciferase. The expression constructs used include pcDNA3 expressing full
length FTO (Flag-FTO), the C-terminal fragment of FTO containing sequence 201e505 (Flag-C’FTO) or the N-terminal fragment of FTO spanning aa 1e200 (Flag- N’FTO) with or
without pcDNA3 expressing full length TRIP4. The ﬁreﬂy luciferase activity was normalized by renilla luciferase activity and expressed as fold change from control cells expressing
only full-length FTO and the reporter construct.Intriguingly, in spite of signiﬁcant weight gain following the HFD, we
show that losing just one functional copy of Fto was sufﬁcient to
ameliorate the leptin resistance and impaired glucose homeostasis
normally associated with exposure to a HFD and an increase in fat
mass. Previously, palmitoyl-coA has been shown to accumulate in the
hypothalamus of animal models following a HFD [28] and central
administration of palmitate leads to leptin resistance [17]. Mice that
were completely or partially deﬁcient in Fto were resistant to the ef-
fects of central palmitate infusion on leptin’s action on food intake.
Hypothalamic leptin resistance has been reported in both rats and mice
within one to three days of exposure to HFD and prior to substantial
weight gain [29]. In our study we showed that the loss of Fto ame-
liorates the development of central leptin resistance following a high-
fat challenge. Of note, the HFD also engendered a differential distri-
bution of fat between visceral and subcutaneous depots that mirrored
the improved metabolic phenotype observed in FTO deﬁcient miceMOLECULAR METABOLISM 4 (2015) 287e298  2015 The Authors. Published by Elsevier GmbH. This is an o
www.molecularmetabolism.com[30]. This maybe as a result of a role for FTO in fat, with FTO variants
having been shown to be associated with both waist circumference
and BMI [1], [31,32], as well as leading to a variation in the distribution
of adipose tissue as determined by magnetic resonance imaging [33];
although this has not been directly addressed here. Further, this dif-
ferential adipocyte phenotype may also have, in part, impacted upon
the persistent leptin sensitivity seen in the HFD fed Fto-deﬁcient mice.
However, given the fact that leptin sensitivity was also seen in the
acute palmitate treated mice, we believe that the effect is due pri-
marily, if not wholly, to central signalling of FTO. It is well-known that
central leptin signalling can modulate glucose homeostasis [34e36].
The concept of hypothalamic ‘microinﬂammation’, or more accurately
the up-regulation of inﬂammatory markers within the medial basal
hypothalamus, is now recognized as a potentially important process in
the pathogenesis of HFD induced metabolic disorders [37]. For
instance, there are data indicating high-fat feeding can inﬂuence leptinpen access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 295
Figure 6: (continued ).
Original articlesensitivity, through the up-regulation of the Tlr4 [21], Myd88 [17],
Socs3 [38] and Ptp1b [39] in the hypothalamus which consequently
impacts upon metabolic phenotypes [40,41]. Further, pharmacological
or genetic disruption of the NFkB pathways have been shown to
restore leptin sensitivity and reduce adiposity in diet induced obesity
[18]. Consistent with these studies, we demonstrate here that the
consumption of a HFD by WT mice causes an up-regulation of genes in
the NFkB pathway in the hypothalamus. This response is signiﬁcantly
reduced with Fto-deﬁciency in a gene dose-dependent manner.
No difference in leptin sensitivity or NFkB signalling transcription
proﬁle was observed when mice were on standard chow, which is to
be expected if NFkB is the plausible downstream mechanism for the
resistance to leptin observed upon a HFD challenge. NFkB and its296 MOLECULAR METABOLISM 4 (2015) 287e298  2015 The Authors. Published by Eupstream regulator IKKb, are both expressed abundantly in the medial
basal hypothalamus, remain suppressed under chow conditions and
are activated by states of over-nutrition, including HFD and acute
central overload of fatty acid and glucose [18]. This mirrors the
nutritional regulation of Fto mRNA within the medial basal hypothal-
amus; being down-regulated by fasting [4,14,15] and up-regulated by
feeding [42] and a HFD [15], [16].
A low dose of central administration of TNFa has been shown previ-
ously to be able to mimic some of the molecular changes seen within
the hypothalamus after exposure to a HFD [21,23,43]. Our results
show that the activation of NFkB signalling by low dose of TNFa re-
stores the ability of palmitate to induce hypothalamic leptin resistance
in Fto-deﬁciency, suggesting that Fto interacts with key moleculeslsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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along the NFlB pathways to play a role in regulating central leptin
sensitivity. Our data suggest that FTO could be a key molecular
mediator of leptin resistance and lowering or inhibiting FTO activity
may be a plausible therapeutic strategy to improving and/or preserving
leptin sensitivity in obese states.
The domain composition of FTO in vertebrates and several algae
pointed us towards TRIP4, a transcriptional co-activator of NFkB, as a
possible mediator of this phenomenon. Our evidence of physical and
functional interaction between FTO and TRIP4 suggests a possible
mechanism linking FTO to NFkB signalling. Consequently, the up-
regulation of Fto on a HFD appears to play a key role in the develop-
ment of leptin resistance. Interestingly, the brain is the only organ that
expresses high levels of both Fto and Trip4. Additionally, the co-
ordinated down-regulation in NFkB gene expression between WT
and Fto-deﬁcient mice on a HFD is restricted to the hypothalamus, and
is not observed in other brain regions or in the periphery. Our data also
indicate that loss of Fto signalling speciﬁcally impairs HFD-induced
NFkB activation while TNFa-induced NFkB activation appears to
remain intact. Within the hypothalamus Fto is clearly not the sole
activator of NFkB. Rather, our data indicate that FTO regulates NFkB
gene expression speciﬁcally within the hypothalamus, with other brain
regions and peripheral tissues unaffected. We hypothesize that the
interaction with TRIP4 within the hypothalamus provides this
speciﬁcity.
Implicating FTO as being able to functionally interact with the NFkB
signalling pathway adds another role to an increasing list of putative
functions for this molecule. Fto has been characterized as a deme-
thylase with the ability to remove 3 methyl groups from single stranded
nucleic acids [4]. More recent evidence indicates that Fto may also
have a role in the sensing of amino acids [20], which potentially
provides an explanation for the signiﬁcant interaction observed be-
tween FTO genetic variation and dietary protein on appetite and food
cravings [44]. How and if these mechanisms link back into the original
observations of associating genomic variance around the FTO locus
with human pathophysiology remains to be fully determined. Indeed,
recent data focussing on obesity associated variants within FTO have
implicated two neighbouring genes, RPGRIP1L and IRX3, as having a
functional link between the SNP and the observed human phenotypes.
As with Fto, perturbing the expression of these genes in mice results in
a bodyweight phenotype, with homozygous deletion of Irx3 resulting in
a smaller mouse [7] while heterozygous deletion of Rpgrip1l leading to
a mild obesity phenotype [8]. These studies have led to much dis-
cussion as to which of the genes close to the loci identiﬁed by the initial
wave of GWAS are responsible, either wholly or partially, for associ-
ation with a range of human phenotypic characteristics [45,46]. The
most parsimonious explanation is that a number of genes in this region
play an important role in determining body composition.
This emerging body of work illustrates the complex biology that can
emerge from the deeper exploration of the basis for genomic variants
robustly associated with human adiposity. Whatever the contribution of
FTO itself to the inﬂuence of the polymorphisms within its ﬁrst intron to
human adiposity, it is clear that disturbance of the expression and
function of FTO can inﬂuence the relationship between dietary
composition and fat accumulation, and this supports the notion that
pharmacological modulation of the activity of FTO might have the
potential for therapeutic beneﬁt in a manner that is inﬂuenced by the
nutritional environment.
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